Back to School: How biopharma can reboot drug development. Access exclusive analysis here

IntraBiotics ends iseganan development

IBPI terminated its iseganan development program and is seeking

Read the full 94 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE